A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial

Nachbagauer, Raffael, Feser, Jodi, Naficy, Abdollah, Bernstein, David I., Guptill, Jeffrey, Walter, Emmanuel B., Berlanda-Scorza, Franceso, Stadlbauer, Daniel, Wilson, Patrick C., Aydillo, Teresa, Behzadi, Mohammad Amin, Bhavsar, Disha, Bliss, Carly, Capuano, Christina, Carreño, Juan Manuel, Chromikova, Veronika, Claeys, Carine, Coughlan, Lynda, Freyn, Alec W., Gast, Christopher, Javier, Andres, Jiang, Kaijun, Mariottini, Chiara, McMahon, Meagan, McNeal, Monica, Solórzano, Alicia, Strohmeier, Shirin, Sun, Weina, Van der Wielen, Marie, Innis, Bruce L., García-Sastre, Adolfo, Palese, Peter and Krammer, Florian 2020. A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial. Nature Medicine 27 , pp. 106-114. 10.1038/s41591-020-1118-7

Full text not available from this repository.

Abstract

Seasonal influenza viruses constantly change through antigenic drift and the emergence of pandemic influenza viruses through antigenic shift is unpredictable. Conventional influenza virus vaccines induce strain-specific neutralizing antibodies against the variable immunodominant globular head domain of the viral hemagglutinin protein. This necessitates frequent re-formulation of vaccines and handicaps pandemic preparedness. In this completed, observer-blind, randomized, placebo-controlled phase I trial (NCT03300050), safety and immunogenicity of chimeric hemagglutinin-based vaccines were tested in healthy, 18–39-year-old US adults. The study aimed to test the safety and ability of the vaccines to elicit broadly cross-reactive antibodies against the hemagglutinin stalk domain. Participants were enrolled into five groups to receive vaccinations with live-attenuated followed by AS03-adjuvanted inactivated vaccine (n = 20), live-attenuated followed by inactivated vaccine (n = 15), twice AS03-adjuvanted inactivated vaccine (n = 16) or placebo (n = 5, intranasal followed by intramuscular; n = 10, twice intramuscular) 3 months apart. Vaccination was found to be safe and induced a broad, strong, durable and functional immune response targeting the conserved, immunosubdominant stalk of the hemagglutinin. The results suggest that chimeric hemagglutinins have the potential to be developed as universal vaccines that protect broadly against influenza viruses.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Publisher:	Nature Publishing Group
ISSN:	1078-8956
Date of Acceptance:	2 October 2020
Last Modified:	03 Feb 2021 14:40
URI:	https://orca.cardiff.ac.uk/id/eprint/137186

Citation Data

Cited 141 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item